日前,药明生基与茂行生物美国公司T-MAXIMUM Pharmaceutical(简称:T-MAXIMUM)共同宣布达成战略合作协议。药明生基将为茂行生物的MT-027通用型CAR-T细胞产品在美国提供一体化测试、工艺开发、申报批生产及IND申报等全流程服务。 MT-027产品是茂行生物自主研发的一款靶向B7-H3的同种异体通用型CAR-T细胞治疗产品,适应症...
CEO of T-MAXIMUM. "T-MAXIMUM's mission is to develop UCAR-T product for patients in need, and we are glad to take the full advantage of WuXi ATU's CTDMO platform to accelerate MT-027 testing, process development, manufacturing and IND filing. In the future, we also desire to deepen ...
2023年6月6日,美国马萨诸塞州波士顿,药明生基与茂行生物美国公司T-MAXIMUM Pharmaceutical Inc(简称:T-MAXIMUM)共同宣布达成战略合作协议。 药明生基将为茂行生物的MT-027通用型CAR-T细胞产品在美国提供一体化测试、工艺开发、申报...
T-MAXIMUM &WuXi Advanced Therapies Contract Signing Ceremony. The second on the left isEdward Hu, Chairman and CEO of WuXi ATU, the third on the left isDr. AngelaChen, Chief Business Officer of WuXi ATU ,the first on the left is Dr. David Chang, Chief Technology Officer of WuXi ATU,an...
2023年6月6日,美国马萨诸塞州波士顿,药明生基与茂行生物美国公司T-MAXIMUM Pharmaceutical Inc(简称:T-MAXIMUM)共同宣布达成战略合作协议。 药明生基将为茂行生物的MT-027通用型CAR-T细胞产品在美国提供一体化测试、工艺开发、申报批生产及IND申报等全流程服务。
New production site of Doby Verrolec in Dubai (AE). Focusing Presspart on the pharmaceutical industry. Sale of Truelove & MacLean, Watertown, CT (US). 2006 Westfalia opens a sales office in Shanghai (CN). 2005 Completion of the new production site of Westfalia s.r.o., Hustopece (CZ)...
药明生基与茂行生物美国公司T-MAXIMUM Pharmaceutical Inc(简称:T-MAXIMUM)共同宣布达成战略合作协议。 药明生基将为茂行生物的MT-027通用型CAR-T细胞产品在美国提供一体化测试、工艺开发、申报批生产及IND申报等全流程服务。 MT-027产品是茂行生物自主研发的一款靶向B7-H3的同种异体通用型CAR-T细胞治疗产品,适应症...
these T-cell engagers to target and lyse tumour cells in vivo in a xenograft mouse tumour model. Our approach enables the rapid generation, screening and testing of bi- and multispecific antibodies to facilitate preclinical pharmaceutical development from in vitro discovery to in vivo proof of ...
We report on mechanisms of toxicity and resistance as well as novel engineering and pharmaceutical interventions to overcome these challenges. Looking forward, we discuss new targets and indications for CAR T cell therapy expected to reach the clinic in the next 1–2 years. We also consider ...
This marvellous inhibitor has better physicochemical, pharmaceutical and pharmacokinetic properties than the defined inhibitor vorinostat. Pracinostat has >100-fold more affinity towards HDACs compared to other zinc-dependent metalloenzymes and shows maximum efficacy when used in doublet therapy. Conclusion...